Erik Tingborn

Erik Tingborn is a senior scientist at Scandinavian Biopharma, with extensive experience in biopharmaceuticals and analytical techniques. Previous roles include scientist at Xbrane Biopharma AB, where Erik introduced new analytical techniques and contributed to key aspects of the marketing authorization application for a ranibizumab biosimilar. Experience as a life sciences consultant at agap2 Sweden involved supporting downstream applications for viral vectors, while earlier positions included IT consulting and method development for major biopharmaceutical organizations. Erik also gained foundational experience through a master's thesis focused on ITP-ESI-MS system development at KTH Royal Institute of Technology, where Erik completed a degree from 2011 to 2016.